Provides a concise and critical explanation of why fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is used to treat Covid patients (NIH, 2021). Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI). Yes, it is approved by the Food and Drug Administration (FDA) for the treatment of obsessive-compulsive disorders and is also used for depression and other illnesses. Studies conducted have shown that fluvoxamine has been found to bind to the sigma 1 receptor in immune cells and reduce the production of inflammatory cytokines. In vitro studies of human endothelial cells and macrophages also reduced the expression of inflammatory genes. The Medical Letter (Medical Letter, 2021: 63) states that Sigma1 agonism has been shown to inhibit SARSCoV2 replication and regulate the inflammatory response to sepsis. Theoretically, COVID 19 can prevent the development of life-threatening cytokine storms and acute respiratory distress syndrome. According to the source by K. Hashimoto (NIH, 2021) The sigma 1 receptor in the endoplasmic reticulum plays an important role in intracellular SARSCoV2 replication. Knockouts and knockdowns of SIGMAR1 (Sigma1 receptor encoded by SIGMAR1) cause a significant reduction in SARSCoV2 replication, suggesting that the Sigma1 receptor is an important therapeutic target for SARSCoV2 replication.